Ekso Bionics® Announces Centers of Robotic Excellence Collaborating with Rehabilitation Facilities for Mobility Impaired
June 15 2017 - 8:00AM
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), an industry leader in
exoskeleton technology for medical and industrial use, today
announced a collaboration with four leading rehabilitation
facilities to establish Centers of Robotic Excellence to help
further advance the use of innovative exoskeleton technology for
mobility impaired patients.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/9adfbc05-aa7d-43ca-b76e-fc0ea2b56b9b
As early adopters of state-of-the-art
exoskeleton technology, the centers have committed to provide
peer-to-peer support as reference sites to train other facilities
interested in becoming proficient in innovative approaches to
rehabilitation.
The centers include:
- Barrow Neurological Institute, Phoenix, Arizona
- Good Shepherd Rehabilitation Network, Allentown,
Pennsylvania
- Marianjoy Rehabilitation Hospital, part of Northwestern
Medicine, Wheaton, Illinois
- “Villa Beretta” Centro di Riabilitazione, Costa Masnaga (LC),
Italy (Northeast of Milan)
“Collaborating with leaders in the
rehabilitation community is key to building clinical support on the
benefits of exoskeletons to aid early mobility for stroke &
spinal cord injury,” said Thomas Looby, president and chief
executive officer of Ekso Bionics. “We are proud to work with these
visionaries who are dedicated to helping patients with recovery and
to provide quantifiable insights into the strides they’re making
walking with an exoskeleton.”
Christina Kwasnica, M.D., medical director for
the Barrow Neuro Rehabilitation Center, notes, “The robotic device
allows us to get patients up on their feet earlier. The gains we
see are overwhelming and the positive effects on a patient’s mood
and motivation is unbelievable.”
Each center will also work with Ekso Bionics to
aid in research and development efforts. The Centers of Excellence
will gather clinical evidence and measurable results on
rehabilitation with EksoGTTM and create research protocols for
proving standard of care for exoskeletons for rehabilitation.
“As an early adopter of the EksoGT, we look
forward to mentoring our peers and sharing our knowledge so that
more patients can benefit from this life-changing technology,” said
Frank Hyland, M.S., P.T., executive director of Good Shepherd
Rehabilitation Network and administrator of Good Shepherd
Rehabilitation Hospital. “Good Shepherd has experienced the
economic advantage firsthand with a significant return on
investment, increased market share growth, and a value proposition
that also benefits patients and payers. EksoGT is now the
cornerstone of our rehabilitation program and has helped our
patients take 3 million steps and counting.”
To learn more about the Centers of Excellence
and the EksoGT, visit
http://eksobionics.com/eksohealth/centers-of-excellence/.
About Ekso Bionics®Ekso Bionics
is a leading developer of exoskeleton solutions that amplify human
potential by supporting or enhancing strength, endurance and
mobility across medical, industrial and defense applications.
Founded in 2005, the company continues to build upon its
unparalleled expertise to design some of the most cutting-edge,
innovative wearable robots available on the market. Ekso Bionics is
the only exoskeleton company to offer technologies that range from
helping those with paralysis to stand up and walk, to enhancing
human capabilities on job sites across the globe, to providing
research for the advancement of R&D projects intended to
benefit U.S. defense capabilities. The company is headquartered in
the Bay Area and is listed on the Nasdaq Capital Market under the
symbol EKSO. For more information, visit: www.eksobionics.com.
About Ekso GT™Ekso GT™ is the
first exoskeleton cleared by the FDA for use with stroke and spinal
cord injuries from L5 to C7. The EksoGT with SmartAssist™ software
is the only exoskeleton available for rehabilitation institutions
that can provide adaptive amounts of power to either side of the
patient’s body, challenging the patient as they progress through
their continuum of care. The suit’s patented technology provides
the ability to mobilize patients earlier, more frequently and with
a greater number of high intensity steps. To date, this device has
helped patients take more than 70 million steps in over 130
rehabilitation institutions around the world.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding (i) the plans and objectives of management for
future operations, including plans or objectives relating to the
design, development and commercialization of human exoskeletons,
(ii) estimates or projection of financial results, financial
condition, capital expenditures, capital structure or other
financial items, (iii) the Company's future financial performance
and (iv) the assumptions underlying or relating to any statement
described in points (i), (ii) or (iii) above. Such forward-looking
statements are not meant to predict or guarantee actual results,
performance, events or circumstances and may not be realized
because they are based upon the Company's current projections,
plans, objectives, beliefs, expectations, estimates and assumptions
and are subject to a number of risks and uncertainties and other
influences, many of which the Company has no control over. Actual
results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Factors
that may influence or contribute to the inaccuracy of the
forward-looking statements or cause actual results to differ
materially from expected or desired results may include, without
limitation, the Company's inability to obtain adequate financing to
fund the Company's operations and necessary to develop or enhance
our technology, the significant length of time and resources
associated with the development of the Company's products, the
Company's failure to achieve broad market acceptance of the
Company's products, the failure of our sales and marketing
organization or partners to market our products effectively,
adverse results in future clinical studies of the Company's medical
device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or
maintain regulatory approval to market the Company's medical
devices, lack of product diversification, existing or increased
competition, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit us
at www.eksobionics.com. The Company does not undertake to
update these forward-looking statements.
The photo is also available at Newscom, www.newscom.com, and via
AP PhotoExpress.
Media Contact:
Carrie Yamond
917-371-2320
cyamond@lazarpartners.com
Investor Contact:
David Carey
212-867-1768
investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2024 to May 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From May 2023 to May 2024